NCT01525082 2024-02-06Capecitabine, Temozolomide, and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine TumorsStanford UniversityPhase 2 Completed20 enrolled 15 charts
NCT00227617 2023-05-22Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine TumorsUniversity of California, San FranciscoPhase 2/3 Terminated36 enrolled 14 charts